-

Celltrion Group to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group today announced that the company will be attending the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Jungjin Seo, Chairman, will be speaking in a fireside chat at 3:35 p.m. ET.

Celltrion Group management will be participating in in-person meetings with investors on Monday, September 11, 2023. It will also be taking part in a New York IR roadshow on Tuesday, September 12 and Wednesday, September 13, 2023.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics.

For more information, visit www.celltrion.com

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries.

For more information, please visit: https://www.celltrionhealthcare.com/en-us/

Contacts

For further information please contact:
Lindsey Lucenta
llucenta@apcoworldwide.com
+1 260-444-1306

Industry:

Celltrion Healthcare

Release Versions
English

Contacts

For further information please contact:
Lindsey Lucenta
llucenta@apcoworldwide.com
+1 260-444-1306

More News From Celltrion Healthcare

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for al...

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg

INCHEON, South Korea--(BUSINESS WIRE)--The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS). The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and...

Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in patients with inflammatory bowel disease (IBD). The real-world evidence was presented at the Meet the Expert (MTE) Sessions at UEG 2025, and included presentations from Professor Nicolas Mathieu, Medical Director of MICI Institut Privé, Cliniques des Cèdres and Asso...
Back to Newsroom